Cambridge Cognition completes spin-out of Monument Therapeutics
Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced the completion of the spin-out of Monument Therapeutics Limited, a drug development company applying digital phenotyping to central nervous system disorders. Cambridge Cognition has been incubating Monument Therapeutics since 2018, with early-stage research supported by two Innovate UK []
Cambridge Cognition completes spin-out of Monument Therapeutics
Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced the completion of the spin-out of Monument Therapeutics Limited, a drug development company applying digital phenotyping to central nervous system disorders. Cambridge Cognition has been incubating Monument Therapeutics since 2018, with early-stage research supported by two Innovate UK []